SRGN and breast cancer: We also assessed the prognostic ability of these uEV-mRNA biomarkers by comparing the expressions of SRGN, FLI1, and MACROH2A2 in uEVs from longitudinal urine samples collected from the same BC patients (n = 5) who had experienced clinical surgeries.